TREAT WITH STAQUIS^TM

STAQUIS^TM is indicated for topical treatment of mild-to-moderate eczema in patients 3 months of age and older^2,7

STAQUIS^TM is the first steroid-free topical PDE4 inhibitor in Hong Kong for the treatment of mild-to-moderate eczema.^2,7,8

STAQUIS^TM has been shown to reduce skin inflammation, itchiness and improve the skin barrier⁹

STAQUIS^TM-treated patients achieved greater improvement in signs of eczema than patients who did not use STAQUIS^{TM 10}

STAQUIS^TM should be applied twice daily to areas affected by eczema⁷

Higher percentage of STAQUIS^TM-treated patients achieved clearer skin by Day 8 than patients who did not use STAQUIS^{TM 11}

times daily

apply to affected areas⁷

days

to reduce pruritus¹²

days

to see improvement on symptoms¹¹

days

to achieve clear or almost clear skin according to ISGA scores^*10

weeks treatment period

most patients did not require the use of other topical treatments⁶

*ISGA (Investigator's Static Global Assessment) is 5-point scale that provides a global clinical assessment of eczema by investigator, based on signs and symptoms of the condition (ISGA score: 4=severe, 3=moderate, 2=mild, 1=almost clear, 0=clear).¹⁰

STAQUIS^TM can be used for as long as 48 weeks⁶

Clinical trials have studied patients treated with STAQUIS^TM for as long as 48 weeks:

• 
  of STAQUIS^TM-treated patients did not require the use of other topical treatments over 48 weeks of use⁶
• STAQUIS^TM was also shown with a low risk of side effects over the 48-week period⁶